514 related articles for article (PubMed ID: 33488573)
1. Research Progress Concerning Dual Blockade of Lymphocyte-Activation Gene 3 and Programmed Death-1/Programmed Death-1 Ligand-1 Blockade in Cancer Immunotherapy: Preclinical and Clinical Evidence of This Potentially More Effective Immunotherapy Strategy.
Qi Y; Chen L; Liu Q; Kong X; Fang Y; Wang J
Front Immunol; 2020; 11():563258. PubMed ID: 33488573
[TBL] [Abstract][Full Text] [Related]
2. Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy.
Makuku R; Khalili N; Razi S; Keshavarz-Fathi M; Rezaei N
J Immunol Res; 2021; 2021():6661406. PubMed ID: 33681388
[TBL] [Abstract][Full Text] [Related]
3. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in the clinical development of immune checkpoint blockade therapy.
Ghahremanloo A; Soltani A; Modaresi SMS; Hashemy SI
Cell Oncol (Dordr); 2019 Oct; 42(5):609-626. PubMed ID: 31201647
[TBL] [Abstract][Full Text] [Related]
5. LAG3 (CD223) as a cancer immunotherapy target.
Andrews LP; Marciscano AE; Drake CG; Vignali DA
Immunol Rev; 2017 Mar; 276(1):80-96. PubMed ID: 28258692
[TBL] [Abstract][Full Text] [Related]
6. The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer.
Qiao XW; Jiang J; Pang X; Huang MC; Tang YJ; Liang XH; Tang YL
Front Immunol; 2020; 11():1721. PubMed ID: 33072064
[TBL] [Abstract][Full Text] [Related]
7. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations.
Jiang Y; Chen M; Nie H; Yuan Y
Hum Vaccin Immunother; 2019; 15(5):1111-1122. PubMed ID: 30888929
[TBL] [Abstract][Full Text] [Related]
8. Resistance mechanisms to checkpoint inhibitors.
Weiss SA; Sznol M
Curr Opin Immunol; 2021 Apr; 69():47-55. PubMed ID: 33676271
[TBL] [Abstract][Full Text] [Related]
9. Lymphocyte-activation gene-3, an important immune checkpoint in cancer.
He Y; Rivard CJ; Rozeboom L; Yu H; Ellison K; Kowalewski A; Zhou C; Hirsch FR
Cancer Sci; 2016 Sep; 107(9):1193-7. PubMed ID: 27297395
[TBL] [Abstract][Full Text] [Related]
10. Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy.
Goleva E; Lyubchenko T; Kraehenbuehl L; Lacouture ME; Leung DYM; Kern JA
Ann Allergy Asthma Immunol; 2021 Jun; 126(6):630-638. PubMed ID: 33716146
[TBL] [Abstract][Full Text] [Related]
11. A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints.
Li Y; Li F; Jiang F; Lv X; Zhang R; Lu A; Zhang G
Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27438833
[TBL] [Abstract][Full Text] [Related]
12. Research progress of PD-1/PD-L1 immunotherapy in gastrointestinal tumors.
Sun J; Zheng Y; Mamun M; Li X; Chen X; Gao Y
Biomed Pharmacother; 2020 Sep; 129():110504. PubMed ID: 32768978
[TBL] [Abstract][Full Text] [Related]
13. Functional Exhaustion of HBV-Specific CD8 T Cells Impedes PD-L1 Blockade Efficacy in Chronic HBV Infection.
Ferrando-Martinez S; Snell Bennett A; Lino E; Gehring AJ; Feld J; Janssen HLA; Robbins SH
Front Immunol; 2021; 12():648420. PubMed ID: 34589081
[TBL] [Abstract][Full Text] [Related]
14. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X
Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy and predictive immunologic profile: the tip of the iceberg.
Cunha Pereira T; Rodrigues-Santos P; Almeida JS; Rêgo Salgueiro F; Monteiro AR; Macedo F; Soares RF; Domingues I; Jacinto P; Sousa G
Med Oncol; 2021 Mar; 38(5):51. PubMed ID: 33788049
[TBL] [Abstract][Full Text] [Related]
16. PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy.
Dermani FK; Samadi P; Rahmani G; Kohlan AK; Najafi R
J Cell Physiol; 2019 Feb; 234(2):1313-1325. PubMed ID: 30191996
[TBL] [Abstract][Full Text] [Related]
17. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
18. Cytokines as potential combination agents with PD-1/PD-L1 blockade for cancer treatment.
Rahimi Kalateh Shah Mohammad G; Ghahremanloo A; Soltani A; Fathi E; Hashemy SI
J Cell Physiol; 2020 Jul; 235(7-8):5449-5460. PubMed ID: 31970790
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of primary and acquired resistance to PD-1/PD-L1 blockade and the emerging role of gut microbiome.
Zou R; Wang Y; Ye F; Zhang X; Wang M; Cui S
Clin Transl Oncol; 2021 Nov; 23(11):2237-2252. PubMed ID: 34002348
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 Distribution and Perspective for Cancer Immunotherapy-Blockade, Knockdown, or Inhibition.
Wu Y; Chen W; Xu ZP; Gu W
Front Immunol; 2019; 10():2022. PubMed ID: 31507611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]